

## Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

## EQA round: AP1/18 - Antithrombotic Agents

Dead line: 16.03.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability						
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>

## Set of samples 1

**(108) Apixaban** [µg/L] 20 20 19 95%

Samples and groups	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Sample A1</b>	200	17	8,5	20		CVP	200	9,3	25%	150	250	20	19 95%
(38) IL	216	11	5,0	5	0							5	
(63) Sysmex	196	10	5,2	7	0							7	
(94) Stago	195	2,2	1,1	5	0							5	
Other				3	0							3	

<b>Sample B1</b>	416	27	6,5	20		CVP	416	15	25%	312	520	20	20 100%
(38) IL	435	9,1	2,1	5	0							5	
(63) Sysmex	420	16	3,7	7	0							7	
(94) Stago	400	13	3,2	5	0							5	
Other				3	0							3	

## Set of samples 2

**(109) Dabigatran** [µg/L] 26 26 26 100%

Samples and groups	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Sample A2</b>	101	12	11	26		CVP	101	5,5	25%	75,7	127	26	26 100%
(38) IL	102	8,8	8,6	5	0							5	
(63) Sysmex	101	7,2	7,1	11	0							11	
(94) Stago	107	9,6	9,0	5	0							5	
(149) Siemens (Dade)	98,5	17	17	5	0							5	

<b>Sample B2</b>	303	35	11	26		CVP	303	17	25%	227	379	26	26 100%
(38) IL	335	43	13	5	0							5	
(63) Sysmex	301	24	7,9	11	0							11	
(94) Stago	322	2,20	0,69	5	0							5	
(149) Siemens (Dade)	280	30	11	5	0							5	

## Set of samples 3

**(110) Rivaroxaban** [µg/L] 30 30 28 93%

Samples and groups	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Sample A3</b>	94,9	11	12	30		CVP	94,9	5,0	25%	71,1	119	30	28 93%
(38) IL	90,6	8,2	9,0	7	0							7	
(63) Sysmex	97,6	11	11	14	0							14	
(94) Stago	87,0	10	12	5	0							5	
Other				4	0							4	

<b>Sample B3</b>	299	25	8,3	30		CVP	299	11	25%	224	374	30	30 100%
(38) IL	275	20	7,3	7	0							7	
(63) Sysmex	316	12	3,8	14	0							14	
(94) Stago	296	5,9	2,0	5	0							5	
Other				4	0							4	

st\_kn\_p

End of report

Printed: 22.03.2018